Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts

BACKGROUND: Systemic chemotherapy with gemcitabine and cisplatin is standard of care for patients with metastatic urothelial bladder cancer. However, resistance formation is common after initial response. The protein Src is known as a proto-oncogene, which is overexpressed in various human cancers....

Descripción completa

Detalles Bibliográficos
Autores principales: Vallo, Stefan, Michaelis, Martin, Gust, Kilian M., Black, Peter C., Rothweiler, Florian, Kvasnicka, Hans-Michael, Blaheta, Roman A., Brandt, Maximilian P., Wezel, Felix, Haferkamp, Axel, Cinatl, Jindrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039786/
https://www.ncbi.nlm.nih.gov/pubmed/27677700
http://dx.doi.org/10.1186/s13104-016-2256-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039786/
https://www.ncbi.nlm.nih.gov/pubmed/27677700
http://dx.doi.org/10.1186/s13104-016-2256-3

Ejemplares similares